Status:
COMPLETED
Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
European recommendations indicate to start a conventional synthetic disease modifying antirheumatic drug (csDMARD) as soon as possible to reach the remission in early RA or low disease activity in est...
Eligibility Criteria
Inclusion
- Social security affiliation
- Signed informed consent
- Adult patient (over 18 years old)
- RA according to ACR/EULAR 2010 criteria since less than 6 months
- DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD
- Having an internet access at home and using an email address
Exclusion
- Other arthritis than RA
- To participate to a blind-randomized study to assess RA treatment
- Pregnancy or breastfeeding
- Patient unable to understand the study, unable to give consent
- Patient deprived of liberty or patient under guardianship
- Patient refusing to participate in the study
- Patients having difficulty using connected objects
Key Trial Info
Start Date :
June 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04749160
Start Date
June 4 2021
End Date
February 20 2022
Last Update
January 18 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Besancon
Besançon, France, 25000
2
Hôpital Pellegrin
Bordeaux, France
3
Clinique de l'Infirmerie Protestante deLyon
Caluire-et-Cuire, France
4
Centre Hospitalier Universitaire de Clermont Ferrand
Clermont-Ferrand, France, 63000